Favipiravir-based regimen for coronavirus disease 2019 pneumonia for a 47-day-old male newborn

Coronavirus disease 2019 pneumonia in the newborn is a difficult-to-treat condition. Early clinical signs of pneumonia are nonspecific and present as respiratory distress of varying severity, and tachypnea is a predominant clinical sign. A 47-day-old, asymptomatic male newborn of coronavirus disease...

Full description

Saved in:
Bibliographic Details
Published in:SAGE open medical case reports 2020-10, Vol.8
Main Authors: Moolasart, Visal, Wongsawat, Jurai, Phokhom, Priyanut, Thienthong, Varaporn
Format: Article
Language:English
Subjects:
Antiretroviral drugs
Antiviral drugs
Case Report
Case reports
Coronaviruses
COVID-19
Pneumonia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease 2019 pneumonia in the newborn is a difficult-to-treat condition. Early clinical signs of pneumonia are nonspecific and present as respiratory distress of varying severity, and tachypnea is a predominant clinical sign. A 47-day-old, asymptomatic male newborn of coronavirus disease 2019 infected mother tested positive for coronavirus disease 2019 by reverse transcription polymerase chain reaction. During hospitalization, he developed progressive tachypnea, tachycardia, and chest radiography abnormalities, and was diagnosed as coronavirus disease 2019 pneumonia. He was treated with favipiravir, hydroxychloroquine, and lopinavir/ritonavir. A favipiravir-based regimen may be the drug of choice for coronavirus disease 2019 pneumonia in the newborn.
ISSN:2050-313X
2050-313X
DOI:10.1177/2050313X20964046